Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Dare Bioscience Inc (DARE)

24 + Investors. Track Smart Money conviction in DARE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
1Q ▼
Buyers last Q
50%

Smart Money Signals — DARE

Based on 24 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their DARE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 89% of 3.0Y peak

89% of all-time peak
24 funds currently hold this stock — 89% of the 3.0-year high of 27 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding DARE is almost the same as a year ago (+0 funds, +0% change). No significant rush to buy or sell — institutional backing is holding steady.
🟡

Slight buying edge — 50% buying

11 buying11 selling
Last quarter: 11 funds bought or added vs 11 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 1 → 4 → 11 → 5. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 38% entered in last year

■ 12% conviction (2yr+) ■ 50% medium ■ 38% new
Only 3 funds (12%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
➡️

Steady discovery — ~5 new funds/quarter

1 → 1 → 4 → 11 → 5 new funds/Q
New funds entering each quarter: 1 → 4 → 11 → 5. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 12% veterans, 42% new entrants

■ 12% veterans ■ 46% 1-2yr ■ 42% new
Of 24 current holders: 3 (12%) held 2+ years, 11 held 1–2 years, 10 (42%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 28% AUM from major funds

28% from top-100 AUM funds
6 of 24 holders rank in the top 100 by AUM, accounting for 28% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — DARE

In 2026 Q1, 11 hedge funds were net buyers of DARE (5 opened a new position, 6 added to an existing one), while 11 reduced or exited (3 trimmed, 8 sold completely) — a 50% buyer ratio, indicating a slight buying edge. 28% of total institutional value in DARE is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 24.

Hedge Fund Ownership: DARE

How many hedge funds hold DARE — quarterly history vs. share price
Quarterly hedge fund ownership of DARE vs. share price

Market Analysis: DARE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: DARE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Dare Bioscience Inc (DARE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much DARE has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
DARE
nan%
XLV
+2.1%

DARE outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
DARE
nan%
XLV
+3.2%

Since the filing became public, DARE outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 0 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: DARE
24 + Investors

Track Smart Money conviction in DARE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 24 27 -11.11%
13F Shares 1M 986K 5.42%
Total Value $2M $2M -0.37%
New Positions 5 11 -6
Increased Positions 6 4 +2
Closed Positions 8 4 +4
Reduced Positions 3 6 -3
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: DARE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

24 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DARE. Verified SEC 13F-HR filings.

QUARTER:
Top 20 DARE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Objectivity Squared, LLC 0.01% 10,915 $20K
2 IFS Advisors, LLC 0.00% 950 $2K
3 XTX Topco Ltd 0.00% 22,339 $41K
4 US Bancorp \de\ 0.00% 91,370 $166K
5 Farther Finance Advisors, LLC 0.00% 9,325 $18K
6 Two Sigma Advisers, LP 0.00% 17,900 $35K
7 SBI Securities Co., Ltd. 0.00% 645 $1K
8 Vanguard Fiduciary Trust Co 0.00% 65,938 $120K
9 Renaissance Technologies LLC 0.00% 10,195 $19K
10 Vanguard Capital Management LLC 0.00% 462,305 $841K
11 Two Sigma Investments, LP 0.00% 13,279 $24K
12 Caldwell Sutter Capital, INC. 0.00% 17 —
13 UBS Group AG 0.00% 43,363 $79K
14 Raymond James Financial Inc 0.00% 15,334 $28K
15 LPL Financial LLC 0.00% 14,639 $27K
16 Susquehanna International Group, LLP 0.00% 17,130 $31K
17 Inspire Investing, LLC 0.00% 14 —
18 Mather Group, LLC. 0.00% 85 —
19 Caitong International Asset Management Co., Ltd 0.00% 2 —
20 BlackRock, Inc. 0.00% 16,971 $31K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Dare Bioscience Inc (DARE)

What does the Smart Money Trend signal show for DARE?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their DARE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for DARE?

Slight buying edge — 50% buying: Last quarter: 11 funds bought or added vs 11 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for DARE holders?

Strong quality — 28% AUM from major funds: 6 of 24 holders rank in the top 100 by AUM, accounting for 28% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held DARE?

Mostly new holders — 38% entered in last year: Only 3 funds (12%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Dare Bioscience Inc (DARE) following the 2026 Q1 hedge fund 13F filings?

As of today, DARE has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), DARE has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →